It will be some time before Sputnik V, the Russia-developed vaccine against the Coronavirus disease (Covid-19), is approval for use in India. “The subject expert committee has sought more data such as the immunogenicity data from the company. The company had presented the safety profile of Phase 2 clinical trials, and interim data from Phase 3 trials. In September 2020, Dr Reddy’s partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of the Sputnik V and for its distribution rights in India. Sputnik V has demonstrated an efficacy rate of 91.6% in the interim analysis of the Phase 3 clinical trials, which included data on 19,866 volunteers in Russia, who received both the first and second dose of the vaccine.

Source: Hindustan Times February 25, 2021 00:50 UTC